SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 2,538.51 |
| Enterprise Value ($M) | 2,250.66 |
| Book Value ($M) | 913.49 |
| Book Value / Share | 11.58 |
| Price / Book | 2.78 |
| NCAV ($M) | 675.40 |
| NCAV / Share | 8.56 |
| Price / NCAV | 3.76 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.12 |
| Return on Assets (ROA) | -0.10 |
| Return on Equity (ROE) | -0.17 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.99 |
| Current Ratio | 5.99 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1,121.71 |
| Assets | 1,359.80 |
| Liabilities | 446.31 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 377.71 |
| Operating Income | -176.49 |
| Net Income | -132.53 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -149.19 |
| Cash from Investing | 71.84 |
| Cash from Financing | 276.45 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | ARCH Venture Fund IX, L.P. | 6.80 | -6.26 | |
| 13G/A | Vanguard Group Inc | 8.79 | 14.21 | |
| 13G/A | Farallon Capital Partners, L.P. | 5.00 | -0.19 | |
| 13G/A | Fmr Llc | 10.98 | 15.25 | |
| 13G/A | Temasek Holdings (Private) Ltd | 3.80 | -15.60 | |
| 13G/A | ARK Investment Management LLC | 11.53 | 14.38 | |
| 13G/A | BlackRock Inc. | 8.20 | 27.18 | |
| 13G | State Street Corp | 5.66 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 258,341 | 921,442 | 28.04 | |
| 519,781 | 1,811,135 | 28.70 | |
| 314,857 | 1,188,654 | 26.49 | |
| 475,051 | 1,683,557 | 28.22 | |
| 192,639 | 879,674 | 21.90 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BBIO – BridgeBio Pharma, Inc. | BCRX – BioCryst Pharmaceuticals, Inc. |
| BDTX – Black Diamond Therapeutics, Inc. | BIIB – Biogen Inc. |
| BLUE – bluebird bio, Inc. |
Financial data and stock pages provided by
Fintel.io